ReviewDiscover oncology2025

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia.

Priya HaysPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.